{"product_id":"mrk-bcg-matrix","title":"(MRK) Merck \u0026 Co., Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Merck \u0026amp; Co., Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the analysis, so you can review the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKeytruda 2024 sales $29.5B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKeytruda generated $29.5 billion in 2024 sales, making it Merck \u0026amp; Co., Inc.'s largest brand and the top PD-1 therapy globally. Its use keeps widening across tumor types and earlier treatment lines, including lung, melanoma, and adjuvant settings. With very high share and still-strong growth, Keytruda fits the Star box in Merck \u0026amp; Co., Inc.'s BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGardasil 9 2024 sales $8.6B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGardasil 9 delivered $8.6B in 2024 sales, making it one of Merck \u0026amp; Co., Inc.’s biggest growth engines. The HPV vaccine still has strong demand in adolescent and adult programs across key markets, even with regional swings. With high share in a growing preventive-care market, it fits the Stars quadrant in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBravecto flea and tick franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBravecto is a top companion-animal parasiticide brand, with 12-week protection that supports repeat use and better compliance. Pet ownership and preventive care keep demand high, and longer treatment cycles help lift refill value. In a large, durable animal-health category, Merck \u0026amp; Co., Inc. can still treat Bravecto as a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNobivac companion animal vaccines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNobivac is a core brand in Merck Animal Health’s vaccine lineup, and that fits a Stars position because pet vaccines are tied to repeat vet visits and booster cycles. Companion-animal vaccine demand stays structurally firm as pet care spend keeps rising, and Nobivac’s wide veterinary channel reach supports share retention.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCore portfolio brand\u003c\/li\u003e\n\u003cli\u003eRecurring booster demand\u003c\/li\u003e\n\u003cli\u003eStrong vet channel presence\u003c\/li\u003e\n\u003cli\u003eFits a growth market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAllflex senseHub digital animal health\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAllflex senseHub fits Stars: Merck Animal Health said the unit generated about $5.8 billion in 2024 sales, and its digital tags and monitoring tools help farmers track animals, cut losses, and improve herd decisions.\u003c\/p\u003e\n\u003cp\u003eLivestock tech spend is rising as producers chase better yield and tighter biosecurity; precision livestock farming demand is growing fast, and connected sensors are moving from niche to core farm tools.\u003c\/p\u003e\n\u003cp\u003eThe business has real momentum in a fast-growing niche, with traceability rules and herd-health pressure making digital ID a must-have, not a nice-to-have.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAbout $5.8B Animal Health sales in 2024\u003c\/li\u003e\n\u003cli\u003eSupports traceability and herd control\u003c\/li\u003e\n\u003cli\u003eDemand rises with biosecurity needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck’s Star Brands: Keytruda and Gardasil 9 Lead the Way\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKeytruda and Gardasil 9 are Merck \u0026amp; Co., Inc.'s clearest Stars: they combine top market share with strong growth, led by 2024 sales of $29.5B and $8.6B. Bravecto, Nobivac, and Allflex senseHub add recurring demand from pets, livestock, and farm tech. These brands sit in growing segments with durable customer use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2024 Sales\u003c\/th\u003e\n\u003cth\u003eStar Signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKeytruda\u003c\/td\u003e\n\u003ctd\u003e$29.5B\u003c\/td\u003e\n\u003ctd\u003eGlobal PD-1 leader\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil 9\u003c\/td\u003e\n\u003ctd\u003e$8.6B\u003c\/td\u003e\n\u003ctd\u003eHigh share, growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMerck \u0026amp; Co. BCG Matrix: clear, quadrant-by-quadrant view of growth, cash, and divestment priorities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMerck \u0026amp; Co., Inc. BCG Matrix, a quick view to pinpoint winners and laggards at a glance\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Merck \u0026amp; Co., Inc., boosting credibility and helping investors verify key assumptions fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBridion anesthesia reversal franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc. reported Bridion sales of about $1.5 billion in 2025, after roughly $1.3 billion in 2024, supported by steady hospital use in anesthesia reversal. Surgical volumes keep demand stable, but growth is not fast. Its strong market position and recurring cash flow make Bridion a clear Cash Cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGardasil 9 mature cash generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGardasil 9 is still a cash machine for Merck \u0026amp; Co., Inc., with 2024 sales of about $8.6 billion and strong margins from global scale. Growth has cooled from the launch years, so the vaccine now looks more like a steady harvest than a high-growth push. High share, mature demand, and slower growth fit classic Cash Cow behavior.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eM-M-R II legacy vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eM-M-R II is a long-established pediatric vaccine and a steady Merck cash cow. Demand stays tied to the routine 2-dose childhood immunization schedule, so volumes are predictable and low growth supports cash generation. With a strong franchise in a mature market, it fits the classic Cash Cow profile.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProQuad childhood vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eProQuad is a cash cow for Merck \u0026amp; Co., Inc.: a long-selling childhood vaccine with mature, recurring demand and little need for heavy promotion. Merck does not report ProQuad revenue separately, but the brand sits in a stable vaccine mix that supports steady cash flow more than fast growth. Its value comes from repeat immunization use, not market expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable demand\u003c\/li\u003e\n\u003cli\u003eLow promo spend\u003c\/li\u003e\n\u003cli\u003eSteady cash flow\u003c\/li\u003e\n\u003cli\u003eMature market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVaqta hepatitis A vaccine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVaqta fits Merck \u0026amp; Co., Inc.'s Cash Cows bucket: hepatitis A is a mature preventive market, so demand is stable and growth is limited. Merck does not separately disclose Vaqta sales in its public filings, which suggests it is a small, steady contributor rather than a major growth engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSteady, mature vaccine demand\u003c\/li\u003e\n\u003cli\u003eUseful for cash generation\u003c\/li\u003e\n\u003cli\u003eNot a main growth driver\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat profile supports a low-investment, harvest-style strategy, with cash used to fund higher-growth assets like oncology and animal health. In BCG terms, Vaqta is a classic cash cow: predictable, defensible, and not built for rapid expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck's Cash Cows Keep the Pipeline Funded\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc.'s Cash Cows are mature, high-share products that keep throwing off cash: Bridion delivered about $1.5 billion in 2025 sales, up from $1.3 billion in 2024, while Gardasil 9 brought in about $8.6 billion in 2024. M-M-R II, ProQuad, and Vaqta add stable, low-growth vaccine cash with limited promo spend. These products fund Merck \u0026amp; Co., Inc.'s R\u0026amp;D and higher-growth bets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2025\/2024 sales\u003c\/th\u003e\n\u003cth\u003eCash Cow signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBridion\u003c\/td\u003e\n\u003ctd\u003e$1.5B \/ $1.3B\u003c\/td\u003e\n\u003ctd\u003eSteady hospital demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGardasil 9\u003c\/td\u003e\n\u003ctd\u003e$8.6B\u003c\/td\u003e\n\u003ctd\u003eMature, high-margin scale\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eMerck \u0026amp; Co., Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Merck \u0026amp; Co., Inc. BCG Matrix report you’ll receive after purchase. What you see here is the final, fully formatted document—no demo content or placeholders. Once purchased, the same file is delivered for immediate use in analysis, presentations, or planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanuvia post patent erosion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJanuvia is a Dog: after U.S. patent loss, generic sitagliptin hit the brand hard, and Merck’s branded share in DPP-4 diabetes therapy has kept falling. The diabetes market is still huge, but Januvia’s growth is flat to negative, and Merck’s 2024 sales for the franchise kept sliding as low-cost copies took volume. Low growth plus weak retained share fit the Dog box.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eJanumet genericized diabetes franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eJanumet sits in Merck \u0026amp; Co., Inc.'s patent-loss phase, and generic sitagliptin-metformin has kept pressure on branded demand. Merck \u0026amp; Co., Inc.'s diabetes franchise now has little strategic upside from this asset, since price and volume both erode after loss of exclusivity. That makes Janumet a clear Dog in the BCG Matrix: low growth, weak value retention, and minimal capital priority.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingulair mature allergy brand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSingulair is a legacy respiratory and allergy brand; after U.S. patent loss in 2012, generics took over most montelukast use. With Merck’s branded share now small and the market mature, it fits Dogs in the BCG Matrix. The 2020 FDA boxed warning on serious neuropsychiatric events also caps growth and keeps pricing weak.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eZetia low share lipid product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eZetia is a mature, low-growth lipid brand in Merck \u0026amp; Co., Inc.'s 2025 portfolio. U.S. generic ezetimibe has largely taken the category, so pricing power and market share are weak. In BCG terms, it fits a \"dog\": limited growth, heavy competition, and little cash-generation value.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow-growth, mature lipid product\u003c\/li\u003e\n\u003cli\u003eGeneric competition dominates\u003c\/li\u003e\n\u003cli\u003eWeak pricing power in 2025\u003c\/li\u003e\n\u003cli\u003eNo longer a cash cow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eVytorin declining combination therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVytorin is a mature legacy lipid-lowering product in Merck \u0026amp; Co., Inc.’s portfolio, but Merck no longer gives it a separate sales line in recent filings, which signals very small scale. In a business that posted $64.2 billion in 2024 revenue, Vytorin’s branded position is weak, growth is limited, and it fits the Dog box: low share, low growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegacy product, no separate 2025 disclosure.\u003c\/li\u003e\n\u003cli\u003eWeak brand power in a mature statin market.\u003c\/li\u003e\n\u003cli\u003eLow-growth, low-share Dog.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck’s Dogs: Patent Loss Leaves These Brands Behind\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eJanuvia, Janumet, Singulair, Zetia, and Vytorin are Dogs because patent loss left them in slow or shrinking markets where generics now win most volume. In Merck \u0026amp; Co., Inc.’s 2024 $64.2 billion revenue base, these brands have weak share, weak pricing power, and little growth. That makes them low-priority assets with limited cash-upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003e2025\/2026 read\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanuvia\u003c\/td\u003e\n\u003ctd\u003eGeneric sitagliptin erodes sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJanumet\u003c\/td\u003e\n\u003ctd\u003ePost-LOE, low growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSingulair\u003c\/td\u003e\n\u003ctd\u003eGeneric-led, boxed warning\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWinrevair 2024 launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWinrevair’s 2024 launch in pulmonary arterial hypertension fits a Question Mark: it entered a clinically important, growing niche, but Merck is still early in share build. In STELLAR, it cut pulmonary vascular resistance by 34.6% and lifted 6-minute walk distance by 40.8 meters, supporting demand. Merck is still spending heavily to drive adoption after the 2024 launch, so cash use stays high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapvaxive 2024 launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCapvaxive, Merck’s 21-valent adult pneumococcal vaccine approved in 2024, targets a broad prevention market and fits a Question Mark in the BCG Matrix. Early uptake is still small versus the large U.S. adult base eligible for pneumococcal vaccination, so near-term returns remain uncertain even as the product has clear long-term upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnflonsia 2025 RSV launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEnflonsia entered the infant RSV prevention market in 2025, after FDA approval in June 2025, so Merck \u0026amp; Co., Inc. is still in the launch phase. RSV is a large, high-growth category, with the CDC estimating 58,000 to 80,000 hospitalizations each year in U.S. children under 5. But Enflonsia’s current share is still low, so the brand has high upside but weak present scale. That makes it a classic Question Mark in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMK-0616 oral PCSK9 inhibitor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMK-0616 sits in a huge pool: cardiovascular disease causes about 20.5 million deaths a year worldwide, and LDL-C lowering is still a core prevention market. An oral PCSK9 inhibitor could be disruptive versus injected drugs, but Merck \u0026amp; Co., Inc. still has no sales here, so this is a clear high-upside Question Mark.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHuge CVD market, but no revenue yet.\u003c\/li\u003e\n\u003cli\u003eOral route could improve uptake.\u003c\/li\u003e\n\u003cli\u003eStill in development, so risk stays high.\u003c\/li\u003e\n\u003cli\u003eNeeds proof on efficacy, safety, and access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTulisokibart pipeline asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTulisokibart targets immune-mediated diseases, a large market, but Merck \u0026amp; Co., Inc. has not yet shown commercial sales or share for this asset. With the business case still being proven, it fits the Question Mark box in the BCG Matrix. The key test is conversion from clinical promise to revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge market, unproven share.\u003c\/li\u003e\n\u003cli\u003eNo disclosed sales yet.\u003c\/li\u003e\n\u003cli\u003eUpside depends on adoption.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMerck’s Big Growth Bets Still Need to Prove Themselves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMerck \u0026amp; Co., Inc.’s Question Marks are growth bets with little or no current share: Winrevair, Capvaxive, Enflonsia, MK-0616, and tulisokibart. They sit in big markets, but most are still in launch or development, so revenue is low and spend stays high. The upside is real, but each asset still must prove adoption, safety, and pricing.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eBCG fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWinrevair\u003c\/td\u003e\n\u003ctd\u003e2024 launch\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapvaxive\u003c\/td\u003e\n\u003ctd\u003e2024 approval\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnflonsia\u003c\/td\u003e\n\u003ctd\u003e2025 approval\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57191834976521,"sku":"mrk-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/mrk-bcg-matrix.webp?v=1783678565","url":"https:\/\/dcfanalyst.com\/products\/mrk-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}